Naftopidil dihydrochloride structure
|
Common Name | Naftopidil dihydrochloride | ||
---|---|---|---|---|
CAS Number | 57149-08-3 | Molecular Weight | 392.491 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 602.8±55.0 °C at 760 mmHg | |
Molecular Formula | C24H30Cl2N2O3 | Melting Point | 212-213° | |
MSDS | N/A | Flash Point | 318.3±31.5 °C |
Use of Naftopidil dihydrochlorideNaftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia[1]. |
Name | 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol,dihydrochloride |
---|---|
Synonym | More Synonyms |
Description | Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia[1]. |
---|---|
Related Catalog | |
Target |
α1-adrenoceptor[1] |
In Vitro | Naftopidil dihydrochloride suppresses human prostate tumor growth by altering interactions between tumor cells and stroma[1]. Naftopidil dihydrochloride (10 μM for PCa cells; 0.1-10 Μm for PrSC) shows growth inhibitory effects on PrSC and PCa cells[1]. Naftopidil dihydrochloride (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC[1]. Cell Proliferation Assay[1] Cell Line: PCa cells, PrSC Concentration: 10 μM (PCa cells); 0.1 μM, 1 μM, 10 μM (PrSC) Incubation Time: 3 days Result: Exhibited growth inhibitory effects on PCa cells, PrSC in dose-dependent manners. Western Blot Analysis[1] Cell Line: PCa cells, PrSC Concentration: 50 μM (E9 cells), 25 μM (PrSC) Incubation Time: 48 hours Result: Increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC. |
In Vivo | Naftopidil dihydrochloride (10 mg/kg; p.o; daily, for 28 days) decreases microvessel density (MVD) in E9 + PrSC tumors mice model[1]. Male athymic mice(7-8 weeks), with E9 + PrSC xenograft [1] Animal Model: Male athymic mice(7-8 weeks), with E9 + PrSC xenograft [1] Dosage: 10 mg/kg Administration: Oral administration, daily, for 28 days Result: Decrease tumor weights. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 602.8±55.0 °C at 760 mmHg |
Melting Point | 212-213° |
Molecular Formula | C24H30Cl2N2O3 |
Molecular Weight | 392.491 |
Flash Point | 318.3±31.5 °C |
Exact Mass | 392.209991 |
PSA | 45.17000 |
LogP | 4.81 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.619 |
Storage condition | -20℃ |
Water Solubility | methanol: >10 mg/mL |
WGK Germany | 3 |
---|---|
RTECS | TL9336500 |
Avishot |
Naftopidil DiHCl |
KT-611 dihydrochloride |
Naftopidildihydrochloride |
RS-1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphthoxy)-2-propanol |
flivas dihydrochloride |
1-(2-Methoxyphenyl)-4-[3-(naphth-1-yloxy)-2-hydroxypropyl]-piperazine |
4-(2-Methoxyphenyl)-a-[(1-naphthalenyloxy)methyl]-1-piperazineethanol |
S1387_Selleck |
Flivas |
1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-(1-naphthyloxy)-2-propanol |
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol |
1-Piperazineethanol, 4-(2-methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]- |
Naftopidil |
1-[4-(2-Methoxyphenyl)piperazin-1-yl]-3-(1-naphthyloxy)propan-2-ol |